Exo-Site Binding Assay for Selective Drug Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional drug discovery methods relying on activity-based assays are inefficient in identifying compounds that bind to exo-sites of proteins, leading to non-selective inhibition of enzymes that process multiple substrates, causing adverse effects.
Innovation Solution
A method involving the use of two protein variants, one wild-type and one mutant, to identify agents that bind specifically to exo-sites through a one-pot library binding or enrichment assay, enhancing the signal-to-noise ratio and facilitating the discovery of selective inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If activity-based assays are used to screen inhibitors, then the throughput and efficiency of drug discovery are improved, but the ability to identify compounds binding to exo-sites deteriorates
Solution Approach 1:
The screening method is segmented into two distinct assays: a primary activity-based assay for high-throughput filtering and a secondary affinity-based assay for specific exo-site binder identification. This segmentation allows each assay to optimize for its specific function, maintaining high throughput while improving detection precision for exo-site binders.
Solution Approach 2:
A probe molecule is introduced as an intermediary that specifically binds to exo-sites and can be detected through affinity-based methods. This intermediary enables the detection of exo-site binding events without interfering with the high-throughput nature of the primary screening, thus resolving the contradiction between throughput and detection capability.
2Strength
If inhibitors are designed to bind at the catalytic site, then binding affinity is improved, but selectivity for specific substrates deteriorates
Solution Approach 1:
The invention targets a specific local region (exo-site) of the protein rather than the general catalytic site. By designing inhibitors that bind to this localized exo-site region, the method achieves both high binding affinity at the target site and high selectivity for specific substrates, avoiding non-selective inhibition of other substrates processed by the same enzyme.
Solution Approach 2:
Instead of targeting the conventional catalytic site for inhibitor binding, the method inverts the approach by targeting the exo-site. This inversion allows the inhibitor to modulate enzyme activity indirectly through allosteric effects while maintaining substrate selectivity, thereby reducing adverse effects from non-selective inhibition.
3Device complexity
If a single substrate mimic is used in activity assays, then the assay complexity is reduced, but the ability to assess selectivity for multiple substrates deteriorates
Solution Approach 1:
The selectivity assessment is segmented into multiple independent affinity-based measurements, each using a different substrate mimic. This allows the complex task of evaluating selectivity across multiple substrates to be broken down into simpler, manageable assays that can be performed sequentially or in parallel, maintaining assay simplicity while achieving comprehensive selectivity evaluation.
Data Source
AI summary
Methods for the identification of agents the bind to exo-sites of proteins are provided. Agents identified by the methods described herein and pharmaceutical compositions comprising the identified agents are also provided. Methods of using an identified agent for the treatment or prevention of a disease, disorder, or condition are also provided, including methods of treating or preventing a disease associated with reduced, elevated, or ectopic expression or aberrant activity of a protein comprising an exo-site.